Published in

Lippincott, Williams & Wilkins, Anti-Cancer Drugs, 1(23), p. 139-140, 2012

DOI: 10.1097/cad.0b013e32834be51a

Links

Tools

Export citation

Search in Google Scholar

Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment.

Journal article published in 2012 by Filip Yves De Vos ORCID, F. Y. F. L. de Vos, Willem Joost Lesterhuis ORCID, Roger Johannes M. Bruggemann, Winette Tita van der Graaf, W. T. A. van der Graaf
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

A patient with metastatic ovarian cancer was treated with liposomal doxorubicin and carboplatin. She had an extravasation during liposomal doxorubicin infusion. Initially, she was treated conservatively with cold compresses and topical treatment. However, because of worsening of symptoms, she received dexrazoxane once daily for 3 days after which complete recovery occurred. This is the first casereport on symptomatic extravasation of liposomal doxorubicin treated with dexrazoxane.